Better-than-expected Q1 21; full-year guidance maintained
06/05/21 -"Benefiting from the strong uptake of the subcutaneous formulation and continued market share gain across lines, Darzalex reported better-than-expected sales in Q1 21 with the ex-US region leading the ..."
Pages
55
Language
English
Published on
06/05/21
You may also be interested by these reports :
10/06/21
When we last teased about Faes Farma (Add, Spain) in July 2020, the small pharma firm was under pressure due to lower demand for its anti-allergy / ...
10/06/21
By gaining 9% over last week, Roche (Add, Switzerland), the largest European pharma by market cap, set the sector on fire. This was overdue as shown ...
09/06/21
With COVID-19 vaccine programmes fast gaining pace, a gradual recovery is expected in the Anti-Histamine markets heading into H2 21, indicating ...
09/06/21
Recently, there has been a turnaround in Roche’s fortunes, with its share price outperforming peers. While, fundamentally, Roche had always been a ...